GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TTY Biopharm Co Ltd (ROCO:4105) » Definitions » Gross-Profit-to-Asset %

TTY Biopharm Co (ROCO:4105) Gross-Profit-to-Asset % : 36.42% (As of Sep. 2024)


View and export this data going back to 2001. Start your Free Trial

What is TTY Biopharm Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. TTY Biopharm Co's annualized Gross Profit for the quarter that ended in Sep. 2024 was NT$3,804 Mil. TTY Biopharm Co's average Total Assets over the quarter that ended in Sep. 2024 was NT$10,447 Mil. Therefore, TTY Biopharm Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 36.42%.


TTY Biopharm Co Gross-Profit-to-Asset % Historical Data

The historical data trend for TTY Biopharm Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TTY Biopharm Co Gross-Profit-to-Asset % Chart

TTY Biopharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.25 27.54 29.67 31.98 33.76

TTY Biopharm Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.48 35.29 30.99 31.80 36.42

Competitive Comparison of TTY Biopharm Co's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TTY Biopharm Co's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where TTY Biopharm Co's Gross-Profit-to-Asset % falls into.



TTY Biopharm Co Gross-Profit-to-Asset % Calculation

TTY Biopharm Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=3287.076/( (9600.635+9874.909)/ 2 )
=3287.076/9737.772
=33.76 %

TTY Biopharm Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=3804.4/( (10249.88+10644.722)/ 2 )
=3804.4/10447.301
=36.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


TTY Biopharm Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of TTY Biopharm Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


TTY Biopharm Co Business Description

Traded in Other Exchanges
N/A
Address
No. 3-1, Park Street, 3rd Floor, Nangang District, Taipei, TWN, 11503
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.

TTY Biopharm Co Headlines

No Headlines